STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the ...

The iron deficiency anemia therapy market is propelled by the increasing ... The growing prevalence of chronic kidney disease ...

Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for its ...

Chronic kidney disease (CKD) is a serious medical condition in which the kidneys slowly lose their ability to work properly, ...

Skin conditions, diet choices, and some chronic health conditions may make the bottom of your feet yellow. Treating the cause ...

Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...

In the U.S., Vafseo® (vadadustat) is approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. Nephrologists in the U.S. began prescribing ...

Drinking green tea is safe for most people but consuming large amounts may raise the risk of iron deficiency anemia, liver problems, and drug interactions ...

Akebia Therapeutics has scrapped plans for trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo, the company said.

A 56-year-old man was admitted to the hospital because of left lower abdominal pain and anemia. He had a 1-year history of ...

Experts participating in the Blood and Beyond initiative call on EU and national policymakers to recognise the importance of ...